“Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland”, Swiss Med Wkly, vol. 149, no. 5152, p. w20170, Dec. 2019, doi: 10.4414/smw.2019.20170.